A 36-year-old man presented with a history of a slowly enlarging painless nasal bulbar conjunctival swelling, noticed over a period of a few months. There was no abnormal skin pigmentation. Apart from slight discomfort there was no other ocular complaint. Examination of the eye was unremarkable except for a pink gelatinous, cystic, fluctuant, non-tender mass approximately 1 cm X 1 cm in dimension extending into the anterior orbit beneath the conjunctiva (Fig. 1) . The mass was freely mobile over the sclera. An attempt to aspirate the fluid failed and did not deflate the lump. The mass was removed through a conjunctival incision; it was gelatinous in texture and was not encapsulated.
An echocardiogram showed an abnormal thickening of the inter-atrial septum, although there was no evidence of myxoma. Early myxoma could not be entirely excluded and it was decided to follow up this patient with regular echocardiograms. During his early twenties he had Zollinger-Ellison syndrome. A gastrin-secreting gastrinoma of the pancreas was removed surgically and confirmed on histology. Screening of first-degree relatives was normal.
Pathological examination
The biopsy showed a well-circumscribed hypocellular lesion composed of stellate and spindle-shaped cells scattered in a myxoid matrix (Fig. 2 ). Capillaries were scattered throughout the lesion. Mitotic figures were not seen and there was no evidence of necrosis. The lesion did not possess a true capsule, but there was a tendency to condensation of collagen at the edge. No inflammatory response was seen and there was no evidence of any other tissue component such as nerve sheath or cartilage. The myxoid matrix stained with alcian blue (Fig. 3 ) and this staining reaction was abolished by hyaluronidase.
Immunohistochemistry demonstrated expression of vimentin and CD34 by the tumour cells. There was no expression of S100, desmin, myoglobin, GFAP, cytokeratin or factor VII related antigen. A diagnosis of myxoma was made.
Discussion
We report a case of conjunctival myxoma associated with Zollinger-Ellison syndrome and thickening of the inter atrial septum. As far as we are aware, this is a novel association.
Myxoma may involve the conjunctiva, orbit, cornea and lid ? -ll Conjunctival myxomas are rare and may present as a painless, freely mobile, slowly growing cystic mass that may extend to the orbit. Aspiration of the contents is not possible. Although benign, conjunctival myxoma may clinically simulate lymphangioma, amelanotic naevus, lymphoma, reactive lymphoid hyperplasia and lipoma.
The majority of reported bulbar conjunctival myxomas occurred on the temporal side and have less frequently affected the nasal side or the inferior and superior bulbar conjunctiva. 3A12 , 13 These well circumscribed lesions arise from the substantia propria and are covered by conjunctival epithelium. 3 , 4 , 13 , 14 Very often conjunctival myxomas are initially diagnosed clinically as cysts. They are pink in colour and can be fleshy in appearance ? A , 12 -14 The cut surface is viscid and gelatinous in nature, The dimensions may vary from 4 to 16 mm, There is no sex preponderance and the median age is 50 years, ranging from 20 to 77 years.
Histologically, myxomas consist of scattered stellate cells disposed in a mucinous proteoglycan matrix with a network of reticulin fibres. I , 12 -IS The stroma stains with alcian blue and on pre-treatment with hyaluronidase becomes alcian blue negative, confirming its hyaluronic acid content. The presence of mast cells is an additional histological feature in conjunctival myxomas. Ultrastructurally the spindle-shaped cells show elongated cytoplasmic processes and are enmeshed in amorphous extracellular material containing sparse collagen fibres. I , 7 , 14 Immunocytochemical studies on our case demonstrated expression of vimentin, a non-specific mesenchymal marker, and CD34. CD34 is a transmembrane glycoprotein which has been used as an endothelial marker, but which may, in fact, be expressed by a much broader range of soft tissue tumours ? The tumour cells in our case did not express factor VIII related antigen. In contrast, expression of factor VIII related antigen has been described in cardiac myxomas, !6 although this is controversial; other authors suggest that surface cells may stain but that the tumour cells themselves do not express this antigen. 17 Microscopically the differential diagnosis of myxoma includes tumours with a myxoid component including myxolipoma, myxochondroma and myxoid neurofibroma. ! In these entities tumours cells actively elaborate mucin rather than it being a degenerative phenomenon, and the term 'myxoid degeneration' is rather inappropriate. I More importantly the true myxoma may be mistaken for richly myxoid malignant tumours such as myxoid liposarcoma, rhabdomyosarcoma, myxoid malignant fibrosarcoma and myxoid chondrosarcoma ? Careful search for the specific cellular elements and rich vascularity of malignant tumours will be helpful in the differential diagnosis. ! Table 1) ." e car lac myxomas m this syndrome tend to occur early in life compared with isolated cardiac myxomas. 8 , 20 , 22 The endocrine overactivity includes Cushing's syndrome, acromegaly and sexual precocity. The schwannomas of this complex affect the upper gastrointestinal tract and the h . h' 22 sympat ebc c am.
Not all patients develop all the features of the above complex. Superficial myxomas involving the lids and conjunctiva occur in nearly 37% of the cases ? O Carney recommended two or more of the following conditions occurring in a characterised fashion for diagnosis: myxoma -cardiac, cutaneous, mammary; spotty skin pigmentation; Cushing' syndrome; acromegaly or gigantism; sexual precocity; or psammomatous melanotic schwannoma ? O The patient we report had Zollinger-Ellison syndrome, due to gastrinoma of the pancreas and histologically proven conjunctival myxoma. Although there was no frank evidence of cardiac myxoma, the inter-atrial septal thickening was unusual and early myxoma could not be ruled out. It is possible that this may represent early myxoma and the patient is under regular review. The patient we report did not fulfil the (lment criteria of Kennedy et al. 2o and Zollinger-Ellison rt;yndrome is not a known endocrine anomaly of the ( arney complex. However, based on the lineage of neural crest cell development, an interesting pattern emerges. Myxomas are of mesenchymal origin and the major proportion of ocular and peri-ocular mesenchymal tissues are derived from neural crest. 23 Gastrinomas arise from APUD cells in the gastrointestinal system, which also originate from neural crest cells ? 4 Schwannomas are benign neoplasms of Schwann cells and involve the upper gastrointestinal tract and the sympathetic chain when they occur as part of Carney complex ? 2 The generation of Schwann cells has been clarified recently as being from neural crest cells ? S Developmentally the cellular origins of myxoma, schwannoma and gastrinoma can be traced to a final common neural crest origin. 23 -2s We propose the criteria of the Carney complex may have to be modified to include endocrinopathies of the diffuse endocrine system such as Zollinger-Ellison syndrome.
In the Carney complex the ophthalmic manifestations precede embolic incidents originating from cardiac myxomas and Carney 22 found more than 50% of the patients with this complex suffered a significant embolic event. Recognition of ocular signs may initiate timely screening which may avert catastrophic acute vascular events such as central retinal artery occlusion and embolic stoke ? O The factors that should increase suspicion are presence of a deeply pigmented lesion (not induced by sun exposure) on the caruncle, conjunctival semilunar folds associated with conjunctival and lid myxomas ? , 8 , 20 Further this complex is inherited as an autosomal dominant trait and screening of the firstd Whilst infrequent, myxomas should be included in the differential diagnosis of slowly growing painless peri-ocular masses; the diagnosis should be confirmed histologically. A cardiac, endocrine and family screening would be appropriate to reduce the risk of morbidity and mortality.
